Hengrui Pharmaceuticals: HRS4800 tablets have been approved for clinical trials of the drug

On January 20, Hengrui Pharmaceuticals announced that it had recently received approval from the State Drug Administration to issue a "Notice of Approval for Clinical Trials of Drugs" for HRS4800 tablets, which will be conducted in the near future.
HRS4800 can affect the conduction of pain signals and play an analgesical role.
is intended for acute and chronic pain.
currently available worldwide without targeted drugs.
foreign countries have similar products in the clinical research and development stage.
domestic and foreign products are now listed for sale, there is no sales data.
addition, the company is conducting Phase I clinical studies of the product in Australia.
, the product has invested a cumulative total of about 27.03 million yuan in research and development.
in accordance with the relevant laws and regulations of China's drug registration requirements, drugs after obtaining the drug clinical trial approval notice, still need to carry out clinical trials and by the State Drug Administration review, approval and approval before production and listing.